842131-33-3

Basic information

• Product Name: TZP 101
• Synonyms: TZP 101;UliMorelin;(7R,10R,13S,16R)-13-cyclopropyl-7-[(4-fluorophenyl)methyl]-10,11,16-trimethyl-17-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-6,9,12-trione
• CAS NO: 842131-33-3
• Molecular Formula: C30H39FN4O4
• Molecular Weight: 538.6534632
• Mol File: 842131-33-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TZP 101(CAS DataBase Reference)
• NIST Chemistry Reference: TZP 101(842131-33-3)
• EPA Substance Registry System: TZP 101(842131-33-3)

Safety Data

• Hazardous Substances Data: 842131-33-3(Hazardous Substances Data)

Upstream product

• 874336-45-5 C₂₅H₃₂N₂O₅*ClH 
• 874336-39-7 C₂₀H₂₃FN₂O₃*ClH 
• 1284151-25-2 C₄₅H₅₃FN₄O₇ 
• 874336-42-2 (R)-2-((R)-2-((S)-2-(((R)-2-(2-(3-aminopropyl)phenoxy)propyl)-amino)-2-cyclopropyl-N-methylacetamido)propanamido)-3-(4-fluorophenyl)propanoic acid 
• 203732-76-7 C₁₆H₁₆FNO₂ 
• 49606-99-7 (S)-2-amino-2-cyclopropylacetic acid 
• 18125-46-7 (R)-4-fluorophenylalanine 
• 874336-35-3 C₃₁H₄₂N₂O₇ 
• 138326-68-8 (S)methyl 2-amino-2-cyclopropylacetate hydrochloride 
• 1351469-17-4 C₄₂H₅₅FN₄O₇ 
• 874336-40-0 C₅₀H₆₁FN₄O₉ 
• 874336-36-4 (S)-2-(((R)-2-(2-(3-(((benzyloxy)carbonyl)amino)propyl)phenoxy)-propyl)(tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid 
• 874336-34-2 C₂₆H₃₄N₂O₅ 
• 874336-16-0 (R)-benzyl (3-(2-((1-bromopropan-2-yl)oxy)phenyl)propyl)-carbamate 

Relevant articles and documents

Macrocyclic Modulators of the Ghrelin Receptor

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

SALTS, SOLVATES, AND PHARMACEUTICAL COMPOSITIONS OF MACROCYCLIC GHRELIN RECEPTOR AGONISTS AND METHODS OF USING THE SAME

The present invention provides novel salts and solvates of macrocyclic compounds that bind to and/or are functional agonists of the ghrelin (growth hormone secretagogue) receptor. The invention also relates to polymorphs of these salts and solvates, pharmaceutical compositions containing these salts or solvates, and methods of using the pharmaceutical compositions. These pharmaceutical compositions are useful as therapeutics for a range of disease indications, in particular, for treatment and prevention of gastrointestinal disorders including, but not limited to, postoperative ileus, gastroparesis, including diabetic and postsurgical gastroparesis, opioid bowel dysfunction, chronic intestinal pseudo-obstruction, short bowel syndrome, functional gastrointestinal disorders and gastrointestinal dysmotility, such as that occurring in conjunction with other disease states, in critical care situations or as a result of treatment with pharmaceutical agents. Additionally, the pharmaceutical compositions have application to the treatment and prevention of metabolic and/or endocrine disorders, cardiovascular disorders, central nervous system disorders, bone disorders, inflammatory disorders, hyperproliferative disorders, disorders characterized by apoptosis and genetic disorders.